Prader-Willi syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $7,500	182 Pages	Thelansis Knowledge Partners	November, 2021	THKP17066586

Best Price Guarantee
Price	from $7,500
Length	182 Pages
Publisher	Thelansis Knowledge Partners
Published Date	November, 2021
SKU	THKP17066586

Prader-Willi syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Prader-Willi syndrome Disease overview, pathogenesis, identified and emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Clinical Trial Landscaping, Probable launch date estimation Regulatory framework, Epidemiology; Incidence, Prevalence, and current therapy market share, Order of entry, patient share, Market uptake, Peak patient share, Disease burden, Annual cost of therapy, the market forecast for the USA, Germany, France, Italy, Spain, UK, Japan and China 2020 to 2030

1. Prader-Willi syndrome – Key Findings Summary: 1.1. Clinical findings; 1.1.1. Disease overview; 1.1.2. Therapeutic practices; 1.1.3. Future outlook; 1.2. Commercial findings; 1.2.1. Prader-Willi syndrome market scenario 2020; 1.2.2. Prader-Willi syndrome market scenario 2025; 1.2.3. Prader-Willi syndrome market scenario 2030
2. Prader-Willi syndrome Overview: 2.1. Disease Introduction; 2.2. Pathophysiology; 2.3. Signs and Symptoms; 2.4. Risk Factors; 2.5. Etiology; 2.6. Classification; 2.7. Pathogenesis; 2.8. Diagnosis; 2.9. Complications; 2.10. Treatment Algorithm; 2.10.1. Treatment in US (guidelines); 2.10.2. Treatment in EU-5 (guidelines); 2.10.3. Treatment in Japan (guidelines); 2.10.4. Treatment in China (guidelines); 2.11. Treatment Goals for Prader-Willi syndrome; 2.12. Referral Patterns; 2.12.1. Referral Scenario in US; 2.12.2. Referral Scenario in EU-5; 2.12.3. Referral Scenario in Japan; 2.12.4. Referral Scenario in China; 2.13.Prader-Willi syndrome Prognosis; 2.14.Healthcare burden; 2.14.1. Healthcare burden in US; 2.14.2. Healthcare burden in EU-5; 2.14.3. Healthcare burden in Japan; 2.14.4. Healthcare burden in China; 2.15. Unmet Needs in Prader-Willi syndrome management; 2.16. Market Opportunity for Prader-Willi syndrome; 2.17. KOL Comments on current and upcoming/expected treatment practices in Prader-Willi syndrome
3. Epidemiology: 3.1. Epidemiology Overview; 3.2. Epidemiology by Geography; 3.2.1. Prader-Willi syndrome Epidemiology in US (2019-2030); 3.2.1.1. Incidence of Prader-Willi syndrome; 3.2.1.2. Diagnosed cases; 3.2.1.3. Treatable Patient Pool; 3.2.1.4. Epidemiology Trends; 3.2.2. Prader-Willi syndrome Epidemiology in EU-5 (2019-2030); 3.2.2.1. Incidence of Prader-Willi syndrome; 3.2.2.2. Diagnosed cases; 3.2.2.3. Treatable Patient Pool; 3.2.2.4. Epidemiology Trends; 3.2.3. Prader-Willi syndrome Epidemiology in Japan (2019-2030); 3.2.3.1. Incidence of Prader-Willi syndrome; 3.2.3.2. Diagnosed cases; 3.2.3.3. Treatable Patient Pool; 3.2.3.4. Epidemiology Trends; 3.2.4. Prader-Willi syndrome Epidemiology in China (2019-2030); 3.2.4.1. Incidence of Prader-Willi syndrome; 3.2.4.2. Diagnosed cases; 3.2.4.3. Treatable Patient Pool; 3.2.4.4. Epidemiology Trends; 3.3. Epidemiology Trends (World-wide)
4. Market Outlook: 4.1. US Prader-Willi syndrome Market Forecast 2019-2030; 4.1.1. Market Progression (Futuristic); 4.1.2. Market Trends and Expectations; 4.1.2.1. Worst case scenario; 4.1.2.2. Base Case Scenario; 4.1.2.3. Best Case Scenario; 4.1.3. Drivers and Barriers; 4.2. UK Prader-Willi syndrome Market Forecast 2019-2030; 4.2.1. Market Progression (Futuristic); 4.2.2. Market Trends and Expectations; 4.2.2.1. Worst case scenario; 4.2.2.2. Base Case Scenario; 4.2.2.3. Best Case Scenario; 4.2.3. Drivers and Barriers; 4.3. France Prader-Willi syndrome Market Forecast 2019-2030; 4.3.1. Market Progression (Futuristic); 4.3.2. Market Trends and Expectations; 4.3.2.1. Worst case scenario; 4.3.2.2. Base Case Scenario; 4.3.2.3. Best Case Scenario; 4.3.3. Drivers and Barriers; 4.4. Germany Prader-Willi syndrome Market Forecast 2019-2030; 4.4.1. Market Progression (Futuristic); 4.4.2. Market Trends and Expectations; 4.4.2.1. Worst case scenario; 4.4.2.2. Base Case Scenario; 4.4.2.3. Best Case Scenario; 4.4.3. Drivers and Barriers; 4.5. Italy Prader-Willi syndrome Market Forecast 2019-2030; 4.5.1. Market Progression (Futuristic); 4.5.2. Market Trends and Expectations; 4.5.2.1. Worst case scenario; 4.5.2.2. Base Case Scenario; 4.5.2.3. Best Case Scenario; 4.5.3. Drivers and Barriers; 4.6. Spain Prader-Willi syndrome Market Forecast 2019-2030; 4.6.1. Market Progression (Futuristic); 4.6.2. Market Trends and Expectations; 4.6.2.1. Worst case scenario; 4.6.2.2. Base Case Scenario; 4.6.2.3. Best Case Scenario; 4.6.3. Drivers and Barriers; 4.7. Japan Prader-Willi syndrome Market Forecast 2019-2030; 4.7.1. Market Progression (Futuristic); 4.7.2. Market Trends and Expectations; 4.7.2.1. Worst case scenario; 4.7.2.2. Base Case Scenario; 4.7.2.3. Best Case Scenario; 4.7.3. Drivers and Barriers; 4.8. China Prader-Willi syndrome Market Forecast 2019-2030; 4.8.1. Market Progression (Futuristic); 4.8.2. Market Trends and Expectations; 4.8.2.1. Worst case scenario; 4.8.2.2. Base Case Scenario; 4.8.2.3. Best Case Scenario; 4.8.3. Drivers and Barriers; 4.9. Key Expected Milestones (world-wide) Impacting the Market
5. Competitive Landscape: 5.1. Pipeline Therapies Overview; 5.1.1. Phase III Therapies; 5.1.1.1. Current Status; 5.1.1.2. Trial details, results; 5.1.1.3. Approval Timeline; 5.1.1.4. Likelihood of approval; 5.1.1.5. Expected Product Positioning; 5.1.1.2. All other Phase III Therapies …..; 5.1.1.3. Attribute Analysis of Phase III molecules; 5.1.2. Phase II and Phase I/II Therapies; 5.1.2.1. Current Status; 5.1.2.2. Trial details, results; 5.1.2.3. Approval Timelines; 5.1.3. List of active Pre-clinical Therapies; 5.1.3.1. Status in Prader-Willi syndrome; 5.1.3.2. Company positioning; 5.1.3.2. All other pre-clinical therapies; 5.1.4. List of Inactive/discontinued assets; 5.1.4.1. Business impact of discontinuations on current pipeline; 5.1.5. Potential winners from Prader-Willi syndrome Pipeline; 5.1.5.1. Potential Blockbusters across the pipeline
6. Regulatory/Approval Scenario: 6.1. Regulatory/Approval Framework in US; 6.1.1. Policy Framework; 6.1.2. Payer Expectations; 6.2. Regulatory/Approval Framework in UK; 6.2.1. Policy Framework; 6.2.2. Payer Expectations; 6.3. Regulatory/Approval Framework in France; 6.3.1. Policy Framework; 6.3.2. Payer Expectations; 6.4. Regulatory/Approval Framework in Germany; 6.4.1. Policy Framework; 6.4.2. Payer Expectations; 6.5. Regulatory/Approval Framework in Italy; 6.5.1. Policy Framework; 6.5.2. Payer Expectations; 6.6. Regulatory/Approval Framework in Spain; 6.6.1. Policy Framework; 6.6.2. Payer Expectations; 6.7. Regulatory/Approval Framework in Japan; 6.7.1. Policy Framework; 6.7.2. Payer Expectations; 6.8. Regulatory/Approval Framework in China; 6.8.1. Policy Framework; 6.8.2. Payer Expectations
7. Clinical Trial Assessment – Current and Future Paradigm: 7.1. Distribution of Primary Endpoints across trials; 7.2. Distribution of Secondary Endpoints across trials; 7.3. Evolution and acceptance of surrogate endpoints; 7.4. Key Investigator initiated trials; 7.5. Attrition analysis; 7.5.1. Suspended/Discontinued Assets; 7.5.2. Failed Trials, Reasons and Business Impact; 7.5.3. Terminated Trials, Reasons and Business Impact; 7.5.4. Withdrawn Trials, Reasons and Business Impact; 7.6. Trial enrollment scenario and challenges; 7.7. Clinical Trial Guidance (across geographies)
8. Thelansis Commentary: 8.1. Key Unmet needs in Prader-Willi syndrome; 8.2. Possible Best-case Clinical Trial Strategies; 8.3. Possible Best Case Targeted Product Profile (TPP); 8.4. Possible Best-case Market positioning strategies; 8.5. Possible Best-case Market Access Strategies; 8.6. Possible Best-case LCM Strategies; 8.7. Overall View on Prader-Willi syndrome Market in Dollar Value
9. Report Methodology: 9.1. Secondary research; 9.2. Primary research; 9.3. Data collation; 9.4. Insight Generation
10. About Thelansis: 10.1. Our Capabilities; 10.2. Our Services; 10.3. Our Contacts; 10.4. Disclaimer